中文

凯普生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.13B-6.1%
Gross profit¥0.05B
Operating income¥-0.00B
Net income¥-0.01B
Gross margin43.7%Net margin -5.1%
Revenue Q/Q-31.5%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.07B56.3%
R&D¥0.01B10.6%
SG&A¥0.09B68.6%
Tax & other¥0.00B2.4%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

德艺文创正丹股份透景生命万通智控南京聚隆正元智慧超频三星云股份杭州园林太龙股份金陵体育雷迪克

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies